FDA Approves Noxafil(R) (Posaconazole) Oral Suspension For Prevention of Life-Threatening Fungal Infections In High-Risk Patients
Posted on: Monday, 18 September 2006, 12:00 CDT
NEW YORK, September 18 /PRNewswire/ -- THIS IS A MULTIVU SPECIAL REPORT BROUGHT TO YOU BY SCHERING-PLOUGH CORPORATION. WORLDWIDE, THERE IS AN UNMET MEDICAL NEED FOR NEW WAYS TO PREVENT SERIOUS INVASIVE FUNGAL INFECTIONS - OR IFIS - PARTICULARLY IN HIGH-RISK PATIENTS. THESE FUNGAL INFECTIONS CAN OFTEN LEAD TO HIGHER DEATH RATES IN PATIENTS WITH SUPPRESSED OR IMPAIRED IMMUNE SYSTEMS, SUCH AS STEM CELL TRANSPLANT RECIPIENTS OR CANCER PATIENTS WITH PROLONGED NEUTROPENIA DUE TO CHEMOTHERAPY. NOW, THE FDA HAS APPROVED NOXAFIL, A SAFE AND EFFECTIVE NEW THERAPY TO PREVENT LIFE-THREATENING FUNGAL INFECTIONS IN THESE HIGH-RISK PATIENTS.
DOCTOR JOSEPH ANTIN, DIRECTOR, ADULT STEM CELL TRANSPLANT PROGRAM, DANA-FARBER CANCER INSTITUTE & PROFESSOR OF MEDICINE, HARVARD MEDICAL SCHOOL:
"In patients with a compromised immune system, invasive fungal infections can be quite serious and difficult to treat, therefore it's better if we can prevent them, than treat them once they've become established."
CLINICAL RESEARCH HAS SHOWN THAT PREVENTIVE THERAPY WITH NOXAFIL REDUCES THE NUMBER OF SERIOUS IFIS IN PATIENTS WITH COMPROMISED IMMUNE SYSTEMS.
FOR MORE INFORMATION ABOUT NOXAFIL, AND COMPLETE PRESCRIBING INFORMATION, VISIT WWW.SCHERING-PLOUGH.COM. I'M DANIELLE ADDAIR.
AUDIO PROVIDED BY: SCHERING-PLOUGH CORPORATION
Audio: http://www.prnewswire.com/broadcast/24453/consumer.html
SCHERING-PLOUGH CORPORATION
CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313, EXT. 3 OR EMAIL RADIO@MULTIVU.COM
Web site: http://www.schering-plough.com/
Source: PRNewswire
Related Articles
- Preventing Fungal Infections in HSCT Recipients: Insights from Clinical Cases
- Interim Results From a New Trial of CANCIDAS(R) (Caspofungin Acetate) in Pediatric Patients With Documented Fungal Infections
- Schering-Plough Anti-Fungal Drug Recommended for Approval
- FDA Approves Schering-Plough's Anti-Fungal Drug
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
- Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients With Invasive Fungal Infections
- Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients
- European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (Posaconazole) Oral Suspension for Treatment of Invasive Fungal Infections
 |
 |
User Comments (0)
RSS Feeds